Open Access

Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention

  • Authors:
    • Yingbo Li
    • Hongjin Chang
    • Lina Ni
    • Peng Xue
    • Caixia Li
    • Lin Yuan
    • Hailing Cui
    • Chengyong Yu
  • View Affiliations

  • Published online on: February 22, 2019     https://doi.org/10.3892/etm.2019.7294
  • Pages: 3047-3052
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Effects of thrombelastogram-guided (TEG-guided) clopidogrel and aspirin on major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) were investigated. A retrospective analysis was performed on 203 patients undergoing PCI interventional therapy in the Cardiovascular Medicine of Weihai Central Hospital from February 2015 to September 2016. The patients were treated with clopidogrel and aspirin for anti-thrombus therapy. Among them, 104 patients who had TEG detection of anticoagulant effects for guiding medication were the experimental group, and 99 patients without TEG detection for guiding medication the control group. The coagulation function and the platelet inhibition rate of patients after medication were evaluated and compared between the two groups. The incidence of MACE and bleeding events of patients was counted during three months of follow-up. Patients in the experimental group had higher R (coagulation reaction time) value and K (blood clot formation time) value than those in the control group after treatment (P<0.05), and lower MA (maximum amplitude) value than those in the control group (P<0.05). Patients in the experimental group had higher postoperative platelet inhibition rate than those in the control group (P<0.05). Patients in the experimental group had lower incidence of MACE and bleeding events than those in the control group (P<0.05). Coronary heart disease (CHD) patients after PCI with the TEG-guided dose adjustment of clopidogrel have more satisfactory treatment effects than patients without the TEG guidance. TEG makes the treatment of patients more targeted and is worthy of promotion.
View Figures
View References

Related Articles

Journal Cover

April-2019
Volume 17 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Y, Chang H, Ni L, Xue P, Li C, Yuan L, Cui H and Yu C: Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention. Exp Ther Med 17: 3047-3052, 2019
APA
Li, Y., Chang, H., Ni, L., Xue, P., Li, C., Yuan, L. ... Yu, C. (2019). Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention. Experimental and Therapeutic Medicine, 17, 3047-3052. https://doi.org/10.3892/etm.2019.7294
MLA
Li, Y., Chang, H., Ni, L., Xue, P., Li, C., Yuan, L., Cui, H., Yu, C."Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention". Experimental and Therapeutic Medicine 17.4 (2019): 3047-3052.
Chicago
Li, Y., Chang, H., Ni, L., Xue, P., Li, C., Yuan, L., Cui, H., Yu, C."Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention". Experimental and Therapeutic Medicine 17, no. 4 (2019): 3047-3052. https://doi.org/10.3892/etm.2019.7294